12:30 PM EDT, 03/28/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target price to $259 from $308, 22.7x our 2026 EPS, below BIO's historical forward P/E average of 40.3x. We think this discount is justified by the complex operating environment that the company is operating in. We reduce our 2025 EPS view to $9.69 from $11.28 and our 2026's to $11.42 from $12.65. We think Bio-Rad ( BIO/B ) shares have been under pressure in the last month (down 6.4%) due to NIH funding concerns. Based on the information shared by management during the Q4 earnings call in February, the U.S. academic and government segment makes up roughly a high-single-digit percent of Bio-Rad's ( BIO/B ) revenue. We think the near-term uncertainties in the global operating environment can pressure Bio-Rad ( BIO/B ) more than anticipated. In 2024, the company generated 41% of its 2024 net sales in the U.S. and 59% in international locations. We forecast top-line revenue to decrease by 3.6% Y/Y in 2025 as we expect ongoing headwinds to persist, especially in the first half of the year.